SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness.

ABSTRACT: Acute myeloid leukemia (AML) is a heterogeneous disease with respect to its genetic and molecular basis and to patients´ outcome. Clinical, cytogenetic, and mutational data are used to classify patients into risk groups with different survival, however, within-group heterogeneity is still an issue. Here, we used a robust likelihood-based survival modeling approach and publicly available gene expression data to identify a minimal number of genes whose combined expression values were prognostic of overall survival. The resulting gene expression signature (4-GES) consisted of 4 genes (SOCS2, IL2RA, NPDC1, PHGDH), predicted patient survival as an independent prognostic parameter in several cohorts of AML patients (total, 1272 patients), and further refined prognostication based on the European

SUBMITTER: Nguyen CH 

PROVIDER: S-EPMC6591510 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature